Cubist Pharmaceuticals has announced plans to offer convertible senior notes worth up to $800 million, including overallotments. The firm will use proceeds to fund its purchase of Optimer Pharmaceuticals.
Published in Brief:
Attest Health Care Advisors
|NGS Provider Enrollment Rep||
National Government Services - WellPoint
|Program Manager II||
Tufts Health Plan/Network Health
|Director, Medicare Advantage/Medicare Part D Focus||
|Director of Clinical Research||
Regenesis Biomedical, Inc.